Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Why the Chinese do not play cricket
https://www.youtube.com/watch?v=pLK7_jEVZow
For my sins, I did a degree in Biochemistry, some 37 years ago. I understand the methodology. If this works, which it clearly does, it is going to blow the oncology market wide open, leaving Avacta collecting royalties with little risk AND more importantly NOT having to fund the development (fine-tuning) of all these established drugs. I get it. I really do.
I can see the massive returns .. for years ... that is my problem. I have been sooo excited..
I am hoping for many inflection points .. and looking at the pipeline, the max won't be reached for a number of years. I am assuming 2026 or later. But I would be very happy if it was before then.
#Me Too
I remortgage the house and invested in AVCT. My M&D died recently. I invested all my inheritance and invested in AVCT. I have been an absolute idiot. I was soo certain. Since the sea of red, I have held on. I have not in a position to sell. I am too embarrassed to tell the wife... She knows nowt. Since the recent rises, I have improved my average from 2.1 to 1.3. It has been the most horrific/scary/fun? white knuckle ride ever. So many sleepless nights. I am absolutely obsessed with this company. It's like a drug. No other company on AIM can touch it. I am hoping it will all come good. It is getting closer.. as I tell myself. I still have my pension (safety net). In the future, I am hoping that this investment will dwarf that many times over so that I can relax and retire. I not expecting that till 2026.
I won't repeat this experience again. I am constantly looking at a share price every morning and throughout the day. Is there a self-help group???
I am not joking...
Why not??
Ripley .. AVA6000 update? when? Before Roadshow?? Y/N?
Not many days left. The roadshow is on the 2nd of February at 10.30am
me too.
I did consider inventing an Investment company to gate crash, but not ask questions ... tempting..
You can't predict the unpredictable.. Nobody saw the pulling of the LFT..
There will be some big +ve news .. considering what is coming our way... I can't believe the SP is as low as it is ..
You will have to scroll down to find Avacta..
Professional investors only..
This might help
https://docs.google.com/forms/d/e/1FAIpQLScPO1DbwWepLBCNhlPpiq1_jnaMGYwqzaXD-k_ZmvIft0dBMQ/viewform
Good Luck Everyone
Well it's now Wednesday and the rise so far has been pathetic..
And I am still waiting..
More likely to be on Tuesday next week when the RNSs are released.
It will happen, I am sure. Its like waiting for Santa..
I cant see what this informaion has to do with Avacta??
Did the Roche LFT pass the Porton Down freeze/thaw process and then pig salvia test?? I don't think so ..
what is the point you are trying to make as I have clearly missed it...sorry
Cindercone .. you wrote ..
You really shouldn't be investing if you can't even figure out why the SP has dropped today...
That is not a helpful response when the buys outweigh the sells more than 5 to 1
There are more helpful comments from the others. Thank you to them..
I am at a loss as to why the SP is tanking today, esp, when there is soooo much positivity about? It does not make any sense whatsoever ..
https://docs.google.com/forms/d/e/1FAIpQLScPO1DbwWepLBCNhlPpiq1_jnaMGYwqzaXD-k_ZmvIft0dBMQ/viewform
This might help
When I wrote back about why I was disinvited, I got the following reply from Faezeh Chizari, CIR
Investor Relations
Thank you for contacting CAG regarding our appointment by Avacta. We are being employed to engage on the company’s behalf with the PCB, wealth manager and smaller institutional investor segment that we specialise in. The meetings that we organise are with this investor base and only with regulated entities.
Avacta will be expanding their investor relations programme into other areas, including private investors, later in the year and there will be opportunities for you to hear directly from the company as a result. ..
So the big organisations get information before the general public. That seems a bit unfair. I assume that the important RNSs we are waiting for so eagerly will arrive before the 2nd Feb ...
Keep patient and hold .. or top if you have any more spare funds
They are definitely more proactive ..
No more to add to the post .. it offered different choices
I would like a virtual 1:1 meeting
I would like to attend a virtual group meeting (2nd February @ 10.30am)
I'm interested in this company, but unable to make the dates/will pass this time
I'm not interested in this company
This invite is for institutional investors only. I had an invitation, but when I wrote back and said thank you, I was then disinvited !!!
There will be many inflection points.. hopefully upwards... Be patient.
You will gt max benefit if hold on till 2026 or so..
Avacta will probably get bought out by then..
Avacta (AVCT, £193m Mkt Cap) | 2nd-4th February
**For professional investors only** We are organising an introduction to Avacta roadshow with CEO, Alistair Smith and CFO, Tony Gardiner on the 2nd-4th February. Avacta is an AIM-listed clinical stage oncology company that focuses on developing cancer therapies and diagnostics based on its Affimer and preCISION platforms. The Therapeutics division develops novel cancer immunotherapies combining its two proprietary platforms. The pre|CISION targeted chemotherapy platform releases active chemotherapy directly in the tumour, limiting systemic exposure and side effects associated with many commonly used cancer treatments. The first drug candidate is AVA6000 pro-Doxorubicin, a targeted form of the standard-of-care Doxorubicin which is a $1bn generic drug that is limited by its severe cardiotoxicity issues. With pro-Doxorubicin that is developed through the pre|CISION platform, the drug performance will increase dramatically with more effectiveness on the tumour and a significant reduction in cardiotoxicity. They have recently started dosing their first patients and currently at a stage to test safety and tolerability. The pre|CISION method can be applied to a range of other chemotherapies in a market worth $56.6B with CAGR of 11.50% and the company has already begun to build the pipeline on other drugs, including Velcade ($1.2bn sales) and Paclitaxel ($2.96bn sales). The diagnostic division utilizes the Affirmer platform to develop diagnostic tests, e.g., Antigen Lateral Flow test. Following the strong shift in the diagnostics market towards decentralized testing and health monitoring devices, the division now focuses more on product development. The Affimer platform is a novel class of biotherapeutic based on naturally occurring human protein which is an alternative to antibodies. The platform benefits from a strong competitive advantage as it is designed to address many of the negative performance issues, principally the time taken, reliance on animal`s immune response, poor specificity, size, and cost...